Publications by authors named "C Scheid"

Claim this Profile
P
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial.
Tim Richardson, Elias Mai, Ekaterina Menis, Axel Benner, Diana Tichy, Christof Scheid

Eur J Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.
Hermann Einsele, Philippe Moreau, Nizar Bahlis, Manisha Bhutani, Laure Vincent, Christof Scheid

Adv Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Free Light-Chain Suppression as a Prognostic Marker in Relapsed and Refractory Myeloma Patients Treated With BCMA-Directed CAR-T Cells.
Tim Richardson, Hishan Tharmaseelan, Guido Kobbe, Ben-Niklas Baermann, Tobias A W Holderried, Christof Scheid

EJHaem· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective systematic classification of causes of death in the course of multiple myeloma.
Jia Xiang Jin, Britta Besemer, Büsranur Yilmaz, Mathias Hänel, Roland Fenk, Christof Scheid

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Operational burden and fragmented implementation in CAR T-cell therapy: Insights from a multinational survey by the GoCART Coalition and the JACIE Quality Managers Committee.
Nick van Sinderen, Julie Dolva, Caterina Riillo, Raquel Espada, Christof Scheid

Hemasphere· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis